Navigation Links
Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers
Date:1/4/2011

ORANGEBURG, S.C., Jan. 4, 2011 /PRNewswire/ -- Zeus, Inc., a global leader in material science and high-performance polymer extrusions, announces it has expanded its capabilities and is now able to process Aeos® ePTFE and Electrospun Polymers in a new 5,000-sq-ft Class 7 manufacturing environment. This expansion allows for the processing of these advanced materials in a more controlled environment, resulting in compliance with stricter regulatory standards.

"Medical regulatory bodies are raising the bar on standards for devices in the industry and Zeus is committed to meeting this challenge," said Bob Jennings, Zeus Vice President, Sales and Marketing. "The processing of these advanced materials in a tightly controlled environment ensures that customer products meet the strictest regulatory requirements in the medical device industry."

Zeus is also equipped with a Class 7 Certified 5,000-sq-ft Biomaterials Facility dedicated exclusively to the extrusion, analysis, and characterization of bioabsorbable polymers and other advanced materials. Coupled with the state-of-the-art Biomaterials Facility, this latest Class 7 expansion further boosts Zeus' ability to provide its customers a speed-to-market pathway for their products. This brings Zeus' total Class 7 Certified manufacturing capabilities to 10,000 sq ft of controlled environment operating under ISO 13485 guidelines.

"Zeus is leading the charge in the marketplace by providing support from ideation all the way to polymer characterization for medical device companies," said Bob Ballard, Vice President, Research and Strategic Business Development. "In addition to our ability to process and extrude polymers in a Class 7 environment, we also have a dedicated analytical laboratory that allows us to provide real-time analysis and characterization of polymers while being manufactured."

About Zeus, Inc.:Zeus, Inc. is headquartered in Orangeburg, SC USA. Zeus is a world leader in material science and the production of high-performance polymer tubing used in demanding applications, operating multiple facilities in North America and internationally. Zeus products and services are preferred by companies in medical, automotive, electrical, fluid handling, aerospace, and mechanical markets. For more information, visit http://www.zeusinc.com.Press Contact:Samantha D. Farlow-MoydCommunications Coordinator (803) 268-9500publicrelations@zeusinc.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE Zeus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Crescent Healthcare Expands East Coast Presence
2. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
3. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
4. Hikma Expands its Global Injectables Business - Live Webcast
5. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
6. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
7. Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market
8. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
9. Vital Therapies Expands SILVER Trial to Saudi Arabia
10. Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs
11. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Calif. , Jan. 17, 2017  Protagonist ... announced that it has initiated a global Phase ... an oral peptide that targets alpha4beta7 integrin. The ... study is to evaluate the safety/tolerability and efficacy ... patients with moderate to severe active disease. ...
(Date:1/16/2017)...   Valentin A. Pavlov, PhD , associate investigator, ... CEO of The Feinstein Institute for Medical Research ... the nervous system regulates the immune system, which will ... devices to treat disease and injury. The analysis ... The paper examines various studies which further define ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based Phase ... end-to-end genome assemblies to researchers around the globe. Long considered a “holy ... answering a wide range of scientific questions. The announcement was made today ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):